The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Long-Term Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men1
Open accessAbstract
Transdermal delivery of testosterone (T) represents an effective alternative to injectable androgens. Transdermal T patches normalize serum T levels and reverse the symptoms of androgen deficiency in hypogonadal men. However, the acceptance of the closed system T patches has been limited by skin irritation and/or lack of adherence. T gels have been proposed as delivery modes that minimize these problems. In this study we examined the pharmacokinetic profiles after 1, 30, 90, and 180 days of daily application of 2 doses of T gel (50 and 100 mg T in 5 and 10 g gel, delivering 5 and 10 mg T/day, respectively) and a permeation-enhanced T patch (2 patches delivering 5 mg T/day) in 227 hypogonadal men. This new 1% hydroalcoholic T gel formulation when applied to the upper arms, shoulders, and abdomen dried within a few minutes, and about 9-14% of the T applied was bioavailable. After 90 days of T gel treatment, the dose was titrated up (50 mg to 75 mg) or down (100 mg to 75 mg) if the preapplication serum T levels were outside the normal adult male range. Serum T rose rapidly into the normal adult male range on day 1 with the first T gel or patch application. Our previous study showed that steady state T levels were achieved 48-72 h after first application of the gel. The pharmacokinetic parameters for serum total and free T were very similar on days 30, 90, and 180 in all treatment groups. After repeated daily application of the T formulations for 180 days, the average serum T level over the 24-h sampling period (C(avg)) was highest in the 100 mg T gel group (1.4- and 1.9-fold higher than the C(avg) in the 50 mg T gel and T patch groups, respectively). Mean serum steady state T levels remained stable over the 180 days of T gel application. Upward dose adjustment from T gel 50 to 75 mg/day did not significantly increase the C(avg), whereas downward dose adjustment from 100 to 75 mg/day reduced serum T levels to the normal range for most patients. Serum free T levels paralleled those of serum total T, and the percent free T was not changed with transdermal T preparations. The serum dihydrotestosterone C(avg) rose 1.3-fold above baseline after T patch application, but was more significantly increased by 3.6- and 4.6-fold with T gel 50 and 100 mg/day, respectively, resulting in a small, but significant, increase in the serum dihydrotestosterone/T ratios in the two T gel groups. Serum estradiol rose, and serum LH and FSH levels were suppressed proportionately with serum T in all study groups; serum sex hormone-binding globulin showed small decreases that were significant only in the 100 mg T gel group. We conclude that transdermal T gel application can efficiently and rapidly increase serum T and free T levels in hypogonadal men to within the normal range. Transdermal T gel provided flexibility in dosing with little skin irritation and a low discontinuation rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.
Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., & Russell, D. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116665 · Cited by 727 · cited 1×
“As 5a-reductase is present in nongenital skin (25), the increase in DHT/T ratios in the 100 and”
BackgroundEffect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531
Self-citationEffect of Testosterone Treatment on Bone Mineral Density in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1966 · Cited by 460
Self-citationTestosterone Action, Deficiency, Substitution
Rajfer, J. (2005) · Journal of Urology · doi:10.1097/01.ju.0000163660.02216.be · Cited by 321
Testosterone: Action, Deficiency, Substitution
Nieschlag, S. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511545221 · Cited by 316
Wang, C. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.3.964 · Cited by 190
Self-citationMeikle, A. W. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.74.3.623 · Cited by 185
Meikle, A. W., Arver, S., Dobs, A. S., Sanders, S. W., Rajaram, L., & Mazer, N. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.5.8626843 · Cited by 129
Self-citationArver, S., Dobs, A. S., Meikle, A. W., Caramelli, K. E., Rajaram, L., Sanders, S. W., & Mazer, N. A. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.3071113.x · Cited by 127
Self-citationLong‐term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years
Behre, H. M., von Eckardstein, S., Kliesch, S., & Nieschlag, E. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00705.x · Cited by 122
Cited by
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationIncreased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085805 · Cited by 735
“[20–23]; TT also increases circulating estrogens [24,25] which may play a role in the observed excess of adverse cardiovascular-related events, given that estrogen therapy has been associated with this excess in both men and women.”
Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Berman, N., Hull, L., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032006 · Cited by 656
Self-citationAraujo, A. B., O’Donnell, A. B., Brambilla, D. J., Simpson, W. B., Longcope, C., Matsumoto, A. M., & McKinlay, J. B. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031719 · Cited by 591
Self-citationWang, C., Catlin, D. H., Demers, L. M., Starcevic, B., & Swerdloff, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031287 · Cited by 580
Self-citationAndropause: clinical implications of the decline in serum testosterone levels with aging in men
Matsumoto, A. M. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.2.m76 · Cited by 490
“Recently, a transdermal T gel, AndroGel® (Unimed/ Solvay, Buffalo Grove, IL), became available for T replacement therapy (260,261,466,467).”
BackgroundSelf-citationLow Serum Testosterone and Mortality in Male Veterans
Shores, M. M., Matsumoto, A. M., Sloan, K. L., & Kivlahan, D. R. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1660 · Cited by 487
Self-citationLow testosterone levels are common and associated with insulin resistance in men with diabetes
Grossmann, M., Thomas, M. C., Panagiotopoulos, S., Sharpe, K., MacIsaac, R. J., Clarke, S., Zajac, J. D., & Jerums, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2177 · Cited by 468
“This is consistent with reports in nondiabetic men, where as many as 30% of men will have normal levels when repeated (34).”
ResultPetak, S. M., Nankin, H. R., Spark, R. F., Swerdloff, R. S., Rodriguez-Rigau, L. J., Anderson, R. J., Bergman, D. A., Garber, J. R., Hamilton Jr, C. R., Hershon, K. S., et al. (2002) · Endocrine Practice · doi:10.4158/ep.8.6.439 · Cited by 372
Self-citationRothman, M. S., Carlson, N. E., Xu, M., Wang, C., Swerdloff, R., Lee, P., Goh, V. H. H., Ridgway, E. C., & Wierman, M. E. (2011) · Steroids · doi:10.1016/j.steroids.2010.10.010 · Cited by 248
Self-citationTestosterone replacement therapy: current trends and future directions
Nieschlag, E., Behre, H. M., Bouchard, P., Corrales, J. J., Jones, T. H., Stalla, G. K., Webb, S. M., & Wu, F. C. W. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh035 · Cited by 224
Serum Testosterone Assays—Accuracy Matters
Matsumoto, A. M., & Bremner, W. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032175 · Cited by 217
Self-citationTestosterone for the aging male; current evidence and recommended practice
Jones, H. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s190 · Cited by 204
Testosterone and Growth Hormone Improve Body Composition and Muscle Performance in Older Men
Sattler, F. R., Castaneda-Sceppa, C., Binder, E. F., Schroeder, E. T., Wang, Y., Bhasin, S., Kawakubo, M., Stewart, Y., Yarasheski, K. E., Ulloor, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2338 · Cited by 194
Khera, M., Adaikan, G., Buvat, J., Carrier, S., El-Meliegy, A., Hatzimouratidis, K., McCullough, A., Morgentaler, A., Torres, L. O., & Salonia, A. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.10.009 · Cited by 177
ORIGINAL ARTICLE: Accuracy of calculated free testosterone formulae in men
Ly, L. P., Sartorius, G., Hull, L., Leung, A., Swerdloff, R. S., Wang, C., & Handelsman, D. J. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03804.x · Cited by 172
Self-citationErythrocytosis Following Testosterone Therapy
Ohlander, S. J., Varghese, B., & Pastuszak, A. W. (2018) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2017.04.001 · Cited by 168
Male hypogonadism: Symptoms and treatment
Kumar, P., Kumar, N., Thakur, D., & Patidar, A. (2010) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/0110-5558.72420 · Cited by 142
Hormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1002 · Cited by 132
Cherrier, M. M., Craft, S., & Matsumoto, A. H. (2003) · Journal of Andrology · doi:10.1002/j.1939-4640.2003.tb02708.x · Cited by 117
Self-citationSeftel, A. D., Mack, R. J., Secrest, A. R., & Smith, T. M. (2004) · Journal of Andrology · doi:10.1002/j.1939-4640.2004.tb03169.x · Cited by 108
Sex hormones and skeletal muscle weakness
Sipilä, S., Narici, M., Kjaer, M., Pöllänen, E., Atkinson, R. A., Hansen, M., & Kovanen, V. (2013) · Biogerontology · doi:10.1007/s10522-013-9425-8 · Cited by 106
Andropause: is androgen replacement therapy indicated for the aging male?
Hijazi, R. A., & Cunningham, G. R. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104518 · Cited by 105
Self-citationEfficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men
Kaufman, J. M., Miller, M. G., Garwin, J. L., Fitzpatrick, S., McWhirter, C., & Brennan, J. J. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2011.02265.x · Cited by 70
Bhasin, S., He, E. J., Kawakubo, M., Schroeder, E. T., Yarasheski, K., Opiteck, G. J., Reicin, A., Chen, F., Lam, R., Tsou, J. A., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1434 · Cited by 62
Mazer, N., Bell, D., Wu, J., Fischer, J., Cosgrove, M., & Eilers, B. (2005) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2005.20231.x · Cited by 44
Patient satisfaction with testosterone replacement therapies: the reasons behind the choices
Kovac, J. R., Rajanahally, S., Smith, R. P., Coward, R. M., Lamb, D. J., & Lipshultz, L. I. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12369 · Cited by 42
Swerdloff, R. S., Pak, Y., Wang, C., Liu, P. Y., Bhasin, S., Gill, T. M., Matsumoto, A. M., Pahor, M., Surampudi, P., & Snyder, P. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1542 · Cited by 39
Self-citationTreatment of hypogonadism: Current and future therapies
Thirumalai, A., Berkseth, K. E., & Amory, J. K. (2017) · F1000Research · doi:10.12688/f1000research.10102.1 · Cited by 36
Testosterone administration in older men
Matsumoto, A. M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.02.011 · Cited by 32
Self-citationLiu, P. Y., Lawrence-Sidebottom, D., Piotrowska, K., Zhang, W., Iranmanesh, A., Auchus, R. J., Veldhuis, J. D., & Van Dongen, H. P. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab375 · Cited by 28
Self-citationMatsumoto, A. M., & Bremner, W. J. (2011) · Williams Textbook of Endocrinology · doi:10.1016/b978-1-4377-0324-5.00019-5 · Cited by 18
Self-citationThe Role of 5α-Reductase Inhibition in Men Receiving Testosterone Replacement Therapy
Gruntmanis, U. (2012) · JAMA · doi:10.1001/jama.2012.259 · Cited by 9
Testosterone Therapy for Osteoporosis in Men
Lakshman, K. M., Bhasin, S., & Araujo, A. B. (2010) · Osteoporosis in Men · doi:10.1016/b978-0-12-374602-3.00056-0 · Cited by 1
Metadata
- Authors
- Swerdloff, R. S., Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A. M., Snyder, P. J., Weber, T., Longstreth, J., & Berman, N.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-12
- Volume
- 85
- Issue
- 12
- Pages
- 4500-4510
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1974581869
- Cited by
- 318
- References
- 24
- FWCI
- 10.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.